John Flygare
Head of Antibody Drug Conjugates Discovery Eli Lilly & Co.
Dr. John Flygare is currently Head of the ADC and Large Molecule Innovation Group at Eli Lilly. John has over 25 years of experience in the biotech and pharmaceutical industry. Most recently, John was Chief Scientific Offiicer of Firefly Biologics, a company he co-founded to focus on Degrader-Antibody Conjugates. Prior to FFB, John held leadership roles at Merck and Genentech. John has also lectured extensively at Stanford University where he has taught >30 undergraduate and graduate courses in organic and medicinal chemistry. John has authored or co-authored >100 publications and is an inventor on >50 issued US Patents.
Seminars
Tuesday 4th November 2025
Panelists:
- Evaluating the landscape of ADC therapies: is the risk of innovation now lower than the risk of irrelevancy?
- Assessing hurdles and opportunities to achieve differentiated ADC profiles in crowded ADC payload and target fields
- Delving into novel ADC payloads: what new MoAs are emerging and what has been demonstrated so far?
- Understanding perspectives on the future of ADC development across ADC design, targeting, and precision medicine approaches
